Response after dose increase in patients with imatinib failure
| Outcome . | Total, n = 84 . | Cytogenetic failure, n = 63 . | Hematologic failure, n = 21 . | P . |
|---|---|---|---|---|
| Cytogenetic response, n (%) | ||||
| Any | 50 (60) | 47 (75) | 3 (14) | < .001 |
| Partial* | 10 (14) | 8 (16) | 2 (10) | .77 |
| Complete | 34 (40) | 33 (52) | 1 (5) | < .001 |
| % 2-year | ||||
| EFS | 57 | 65 | 36 | < .001 |
| FFS | 29 | 38 | 5 | < .001 |
| TFS | 73 | 80 | 51 | .004 |
| OS | 84 | 90 | 67 | < .001 |
| Outcome . | Total, n = 84 . | Cytogenetic failure, n = 63 . | Hematologic failure, n = 21 . | P . |
|---|---|---|---|---|
| Cytogenetic response, n (%) | ||||
| Any | 50 (60) | 47 (75) | 3 (14) | < .001 |
| Partial* | 10 (14) | 8 (16) | 2 (10) | .77 |
| Complete | 34 (40) | 33 (52) | 1 (5) | < .001 |
| % 2-year | ||||
| EFS | 57 | 65 | 36 | < .001 |
| FFS | 29 | 38 | 5 | < .001 |
| TFS | 73 | 80 | 51 | .004 |
| OS | 84 | 90 | 67 | < .001 |
EFS indicates event-free survival; FFS, failure-free survival; TFS, transformation-free survival; and OS, overall survival.
Only patients (n = 71) not in MCyR at the time of imatinib dose escalation were evaluable.